Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
| RCUS Stock | USD 8.70 0.39 4.29% |
Slightly above 61% of Arcus Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Arcus Biosciences suggests that many traders are alarmed. Arcus Biosciences' investing sentiment can be driven by a variety of factors including economic data, Arcus Biosciences' earnings reports, geopolitical events, and overall market trends.
HAYWARD, Calif., June 01, 2025--Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology Annual Meeting.
Read at finance.yahoo.com
 |
Arcus Biosciences Fundamental Analysis
We analyze Arcus Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Arcus Biosciences is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Arcus Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arcus Biosciences stock to make a market-neutral strategy. Peer analysis of Arcus Biosciences could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics with similar companies.
Peers
Arcus Biosciences Related Equities
| ABOS | Acumen Pharmaceuticals | 7.02 | ||||
| CNSP | Cns Pharmaceuticals | 2.47 | ||||
| GPCR | Structure Therapeutics | 1.94 | ||||
| PTCT | PTC Therapeutics | 1.19 | ||||
| TCRX | Tscan Therapeutics | 0.65 | ||||
| INZY | Inozyme Pharma | 0.50 | ||||
| XFOR | X4 Pharmaceuticals | 0.37 | ||||
| BPMC | Blueprint Medicines | 0.02 | ||||
| ITOS | Iteos Therapeutics | 0.79 | ||||
| DAWN | Day One | 2.11 | ||||
| KRYS | Krystal Biotech | 2.94 | ||||
| APLS | Apellis Pharmaceuticals | 2.95 | ||||
| MDGL | Madrigal Pharmaceuticals | 3.56 | ||||
| ANNX | Annexon | 4.10 | ||||
| CGEM | Cullinan Oncology | 4.81 | ||||
| IMMX | Immix Biopharma | 5.00 | ||||
| RLAY | Relay Therapeutics | 6.42 |
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.